Compare Medpace Holdings Inc (MEDP) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $528.16 (market cap $15.18B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.78. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | VWO | |
|---|---|---|
Market Cap | $15.18B | — |
Sector | Technology | — |
52-Week High | $620.59 | $61.24 |
52-Week Low | $393.42 | $49.54 |
Enterprise Value | $14.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and oscillators showing neutral readings. The ETF's low expense ratio of 0.06% and a 2.4% dividend yield are key attractions, though financial ratios are unavailable. Recent news highlights emerging markets' record inflows and comparisons with competing funds, emphasizing cost advantages and exposure to developing economies.
Outlook is mixed: strong institutional interest and low costs support long-term growth in emerging markets, but bearish technicals and geopolitical risks in regions like China pose headwinds. Investors should weigh the ETF's diversification benefits against volatility from economic uncertainties and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
